Promoting IDO is a promising method for targeting glioblastoma, which is highly resistant to most of the commonly used cancer treatments and often requires a combination of surgical resection, chemotherapy, radiotherapy, and/or immunotherapy (Minniti et al., 2009). This evidence concerns the gene IDO1 and glioblastoma.